Two-dimensional correlated spectroscopy distinguishes clear cell renal cell carcinoma from other kidney neoplasms and non-cancer kidney.
Renal cell carcinoma (RCC)
magnetic resonance spectroscopy (MRS)
multivariate statistical analysis
principal components analysis
spectroscopy-pathology correlation
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
06
12
2021
accepted:
03
05
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
ppublish
Résumé
Routinely used clinical scanners, such as computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound (US), are unable to distinguish between aggressive and indolent tumor subtypes in masses localized to the kidney, often leading to surgical overtreatment. The results of the current investigation demonstrate that chemical differences, detected in human kidney biopsies using two-dimensional COrrelated SpectroscopY (2D L-COSY) and evaluated using multivariate statistical analysis, can distinguish these subtypes. One hundred and twenty-six biopsy samples from patients with a confirmed enhancing kidney mass on abdominal imaging were analyzed as part of the training set. A further forty-three samples were used for model validation. In patients undergoing radical nephrectomy, biopsies of non-cancer kidney cortical tissue were also collected as a non-cancer control group. Spectroscopy data were analyzed using multivariate statistical analysis, including principal component analysis (PCA) and orthogonal projection to latent structures with discriminant analysis (OPLS-DA), to identify biomarkers in kidney cancer tissue that was also classified using the gold-standard of histopathology. The data analysis methodology showed good separation between clear cell renal cell carcinoma (ccRCC) versus non-clear cell RCC (non-ccRCC) and non-cancer cortical tissue from the kidneys of tumor-bearing patients. Variable Importance for the Projection (VIP) values, and OPLS-DA loadings plots were used to identify chemical species that correlated significantly with the histopathological classification. Model validation resulted in the correct classification of 37/43 biopsy samples, which included the correct classification of 15/17 ccRCC biopsies, achieving an overall predictive accuracy of 86%, Those chemical markers with a VIP value >1.2 were further analyzed using univariate statistical analysis. A subgroup analysis of 47 tumor tissues arising from T1 tumors revealed distinct separation between ccRCC and non-ccRCC tissues. This study provides metabolic insights that could have future diagnostic and/or clinical value. The results of this work demonstrate a clear separation between clear cell and non-ccRCC and non-cancer kidney tissue from tumor-bearing patients. The clinical translation of these results will now require the development of a one-dimensional (1D) magnetic resonance spectroscopy (MRS) protocol, for the kidney, using an
Sections du résumé
Background
UNASSIGNED
Routinely used clinical scanners, such as computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound (US), are unable to distinguish between aggressive and indolent tumor subtypes in masses localized to the kidney, often leading to surgical overtreatment. The results of the current investigation demonstrate that chemical differences, detected in human kidney biopsies using two-dimensional COrrelated SpectroscopY (2D L-COSY) and evaluated using multivariate statistical analysis, can distinguish these subtypes.
Methods
UNASSIGNED
One hundred and twenty-six biopsy samples from patients with a confirmed enhancing kidney mass on abdominal imaging were analyzed as part of the training set. A further forty-three samples were used for model validation. In patients undergoing radical nephrectomy, biopsies of non-cancer kidney cortical tissue were also collected as a non-cancer control group. Spectroscopy data were analyzed using multivariate statistical analysis, including principal component analysis (PCA) and orthogonal projection to latent structures with discriminant analysis (OPLS-DA), to identify biomarkers in kidney cancer tissue that was also classified using the gold-standard of histopathology.
Results
UNASSIGNED
The data analysis methodology showed good separation between clear cell renal cell carcinoma (ccRCC) versus non-clear cell RCC (non-ccRCC) and non-cancer cortical tissue from the kidneys of tumor-bearing patients. Variable Importance for the Projection (VIP) values, and OPLS-DA loadings plots were used to identify chemical species that correlated significantly with the histopathological classification. Model validation resulted in the correct classification of 37/43 biopsy samples, which included the correct classification of 15/17 ccRCC biopsies, achieving an overall predictive accuracy of 86%, Those chemical markers with a VIP value >1.2 were further analyzed using univariate statistical analysis. A subgroup analysis of 47 tumor tissues arising from T1 tumors revealed distinct separation between ccRCC and non-ccRCC tissues.
Conclusions
UNASSIGNED
This study provides metabolic insights that could have future diagnostic and/or clinical value. The results of this work demonstrate a clear separation between clear cell and non-ccRCC and non-cancer kidney tissue from tumor-bearing patients. The clinical translation of these results will now require the development of a one-dimensional (1D) magnetic resonance spectroscopy (MRS) protocol, for the kidney, using an
Identifiants
pubmed: 35958897
doi: 10.21037/tau-21-1082
pii: tau-11-07-929
pmc: PMC9360516
doi:
Types de publication
Journal Article
Langues
eng
Pagination
929-942Informations de copyright
2022 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-21-1082/coif). SJDV received a University of Queensland Research Training Program Scholarship for her PhD studies and a Randal Silcock Bursary for conference travel. CEM has received research grants from Advance Queensland Research, was a consultant for the National Imaging Facility, and is a shareholder for DatChem Pty Ltd. and Goolwa Pty Ltd. The other authors have no conflicts of interest to declare.
Références
Radiology. 2011 May;259(2):540-9
pubmed: 21357517
Sci Rep. 2020 Apr 6;10(1):5955
pubmed: 32249812
Eur J Biochem. 1992 Apr 15;205(2):827-39
pubmed: 1572374
Chem Rev. 2004 Aug;104(8):3677-704
pubmed: 15303833
Radiology. 2010 Sep;256(3):836-46
pubmed: 20720070
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Anesth Analg. 2006 Apr;102(4):1164-8
pubmed: 16551917
Curr Opin Clin Nutr Metab Care. 2018 Jan;21(1):64-70
pubmed: 29211698
Magn Reson Med. 1988 Aug;7(4):463-71
pubmed: 3173061
J Natl Cancer Inst. 2006 Sep 20;98(18):1331-4
pubmed: 16985252
BJU Int. 2011 Mar;107(5):735-740
pubmed: 21054752
J Magn Reson Imaging. 2006 Sep;24(3):459-77
pubmed: 16897689
NMR Biomed. 2000 May;13(3):129-53
pubmed: 10861994
Cancer Cell. 2016 Jan 11;29(1):104-116
pubmed: 26766592
J Urol. 2021 Aug;206(2):209-218
pubmed: 34115531
Am J Surg Pathol. 2003 May;27(5):612-24
pubmed: 12717246
J Kidney Cancer VHL. 2014 Jul 20;1(3):26-39
pubmed: 28326247
Invest Radiol. 2008 Oct;43(10):745-51
pubmed: 18791417
Lancet. 2009 Mar 28;373(9669):1119-32
pubmed: 19269025
Urol Clin North Am. 2017 May;44(2):147-154
pubmed: 28411907
J Cell Biochem. 2003 Oct 15;90(3):525-33
pubmed: 14523987
J Cell Mol Med. 2011 Jan;15(1):109-18
pubmed: 19845817
Am J Physiol Renal Physiol. 2005 Apr;288(4):F637-41
pubmed: 15572523
Ann Transl Med. 2019 Feb;7(3):56
pubmed: 30906760
J Lipid Res. 1987 Oct;28(10):1177-84
pubmed: 3681141
Cancers (Basel). 2019 Aug 24;11(9):
pubmed: 31450600
Ther Apher Dial. 2004 Dec;8(6):468-73
pubmed: 15663546
Oncogene. 2020 Oct;39(42):6556-6571
pubmed: 32917955
Cancer Res. 2015 Jun 15;75(12):2541-52
pubmed: 25952651
Pathology. 1993 Jul;25(3):268-76
pubmed: 7903445
Semin Nephrol. 2020 Jan;40(1):2-13
pubmed: 32130963
Eur Urol. 2018 Apr;73(4):560-569
pubmed: 29325693
Cancer Biol Med. 2014 Sep;11(3):162-72
pubmed: 25364577
Eur Urol. 2015 Mar;67(3):519-30
pubmed: 25449206
J Cancer Res Clin Oncol. 2012 May;138(5):753-61
pubmed: 22258851
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Neuroimage. 2010 Nov 1;53(2):544-52
pubmed: 20600973
Radiology. 2003 Jul;228(1):144-51
pubmed: 12832578
Eur Urol. 2015 May;67(5):913-24
pubmed: 25616710
Urol Oncol. 2020 Oct;38(10):755-762
pubmed: 31155438
Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):
pubmed: 33893240
J Clin Oncol. 2018 Oct 29;36(36):3591-3600
pubmed: 30372390
Ther Adv Neurol Disord. 2019 Oct 19;12:1756286419877081
pubmed: 31666809
Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92
pubmed: 17161157
J Urol. 2014 Nov;192(5):1337-42
pubmed: 24936720